A randomized, sham-controlled clinical trial to evaluate the NET Device™ for reducing withdrawal symptom severity during opioid discontinuation.

Front Psychiatry · 2025 · PMC11880230 · PMID 40046990

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantp <.001actually significant

Mean (± 1 SD) COWS score in the active NET group decreased from baseline (18.1 ± 4.4) to 1-hr (7.0 ± 4.1); this 61.3% decrease was highly significant, t = 15.46, p <.001, Cohen’s d = 2.14, exceeding the pre-specified 15% criterion.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.